Protalix Biotherapeutics Inc., of Carmiel, Israel, said the Brazilian regulator ANVISA granted approval for alfataliglicerase as a long-term enzyme replacement therapy (ERT) for children, 4 and older, with a confirmed diagnosis of type I Gaucher disease. The ERT was approved for adults in March 2013. Gaucher disease is a rare lysosomal storage disorder, with about 700 patients treated in Brazil.